Overall Fundamental outlook

* AJANTPHARM makes the list of companies with the best fundamentals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

AJANTPHARM's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 2.854000
forwardPE 26.502224
debtToEquity 1.251000
earningsGrowth 0.121000
revenueGrowth 0.110000
grossMargins 0.769630
operatingMargins 0.215570
trailingEps 73.580000
forwardEps 99.280000

AJANTPHARM's current ratio of 2.854 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that AJANTPHARM is financially well-prepared to meet its liabilities without difficulty.
AJANTPHARM's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
AJANTPHARM's positive earnings and revenue growth indicate that the company is expected to continue expanding its business. These trends reflect strong financial health, with increasing profits and sales suggesting sustained growth and success for AJANTPHARM.
Positive gross and operating margins for AJANTPHARM demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
AJANTPHARM's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in AJANTPHARM's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

The stock price of Ajanta Pharma Limited has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


In recent market activity, 13 sales of AJANTPHARM shares took place, with market price at 2914.596153846154.During the review period, no sell transactions were executed.With more buying than selling around Ajanta Pharma Limited's current price, investors could be expressing optimism. This trend may suggest that the market expects favorable outcomes for the stock, leading to an increased demand at these levels.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts' buy bias toward AJANTPHARM suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, AJANTPHARM is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.